|
|
| Gene : |
KDR |
| Gene ID : |
3791 |
| Uniprot ID : |
P35968 |
| Alternative Name : |
KDR, FLK1, VEGFR2 |
| Format : |
Purified |
| Amount : |
100 µg |
| Clone name : |
ABM4A88 |
| Isotype : |
Mouse IgG1 Kappa |
| Immunogen Information : |
A partial length recombinant protein from N terminal portion of hVEGFR2 was used as the immunogen for this antibody. |
VEGFR-2 is the major receptor involved in vasculogenesis and angiogenesis that regulates endothelial cell survival, migration, and mitogenesis. After its binding to VEGF, VEGFR-2 dimerizes and undergoes autophosphorylation of tyrosine residues within its cytoplasmic domain, thus initiating the downstream signaling cascades. However, as a therapeutic target, the attractiveness of VEGFR-2 is multifaceted. VEGFR-2 is not only highly expressed on the surface of tumor-related endothelial cells, but also expressed directly on tumor cells. Selective VEGFR-2 blockades can lead to inhibition of receptor phosphorylation and tumor angiogenesis as well as tumor cell apoptosis, which ultimately leads to tumor regression. Importantly, selective inhibition of VEGFR-2, can be tailored to attenuate only specific signal-transduction pathways and do not affect any other RTKs (Receptor Tyrosine Kinases ), so they should eliminate toxicity reactions resulting from off-target receptor inhibitions, which is a frequent phenomenon observed by non-specific inhibitors of VEGF receptors.
Immunohistochemistry: 5-10 µg/ml
